<code id='2145FC5640'></code><style id='2145FC5640'></style>
    • <acronym id='2145FC5640'></acronym>
      <center id='2145FC5640'><center id='2145FC5640'><tfoot id='2145FC5640'></tfoot></center><abbr id='2145FC5640'><dir id='2145FC5640'><tfoot id='2145FC5640'></tfoot><noframes id='2145FC5640'>

    • <optgroup id='2145FC5640'><strike id='2145FC5640'><sup id='2145FC5640'></sup></strike><code id='2145FC5640'></code></optgroup>
        1. <b id='2145FC5640'><label id='2145FC5640'><select id='2145FC5640'><dt id='2145FC5640'><span id='2145FC5640'></span></dt></select></label></b><u id='2145FC5640'></u>
          <i id='2145FC5640'><strike id='2145FC5640'><tt id='2145FC5640'><pre id='2145FC5640'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:knowledge    Page View:3

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In